Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France

Chevaux, Jean–Baptiste; Nani, Abdelbasset; Oussalah, Abderrahim; Venard, Véronique; Bensenane, Mouni; Belle, Arthur; Guéant, Jean‐Louis; Bigard, Marc‐André; Bronowicki, Jean–Pierre; Peyrin–Biroulet, Laurent

doi:10.1002/ibd.21147

Cited by 82 publications

(84 citation statements)

References 45 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 Studies evaluating the prevalence of HBV infection in patients with IBD are summarised in Table 1. 2,[6][7][8][9] The weighted mean prevalence of HBsAg-positive infection in the five studies included (total population, 3121 patients) was 1%. The corresponding mean value for anti-HBcpositive infection was 8.1%.…”

Section: What Is the Prevalence Of Hbv And Hcv Infection In Ibd Patiementioning

confidence: 99%

“…6 Table 2 presents a series of studies evaluating the prevalence of HCV infection in patients with IBD. 2,6,7,[9][10][11] The weighted mean prevalence of anti-HCV-positive infection for the six studies (3575 patients) was 3.3%. When only patients diagnosed with CD were considered, the mean value for anti-HCV was 3.4%, whereas the respective figure for UC patients was 2.7%.…”

Section: Prevalence Of Hcv Infectionmentioning

confidence: 99%

“…36 On the contrary, no definite HBV reactivations have been found in anti-HBc-positive patients lacking HBsAg. 9,36 There is only one report of HBV reactivation in an anti-HBcpositive ⁄ HBsAg-negative patient with CD treated with corticosteroids and infliximab. 37 Therefore, systematic use of anti-viral prophylaxis in anti-HBc-positive patients lacking HBsAg cannot be recommended.…”

Section: How Frequent Is Progression To Liver Cirrhosis In Ibd Patienmentioning

confidence: 99%

“…102 According to the World Health Organization, an anti-HBs concentration of ‡10 mIU ⁄ mL measured 1-3 months after administration of the last dose of the primary vaccination series is considered a reliable marker of protection against infection. 9,77,80,81,97,[102][103][104] As time passes, anti-HBs titres frequently become undetectable. A number of long-term studies performed in different epidemiological contexts have confirmed that clinical HBV infection rarely occurs among successfully vaccinated individuals even though the anti-HBs concentrations decline to <10 mIU ⁄ mL over time.…”

Section: Should Testing For Serological Immunity Be Performed After Hmentioning

confidence: 99%

See 3 more Smart Citations

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease

Gisbert

Chaparro

Esteve

2011

Alimentary Pharmacology &Amp; Therapeutics

105

View full text Add to dashboard Cite

Section: What Is the Prevalence Of Hbv And Hcv Infection In Ibd Patiementioning

confidence: 99%

Section: Prevalence Of Hcv Infectionmentioning

confidence: 99%

Section: How Frequent Is Progression To Liver Cirrhosis In Ibd Patienmentioning

confidence: 99%

Section: Should Testing For Serological Immunity Be Performed After Hmentioning

confidence: 99%

See 2 more Smart Citations

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease

Gisbert

Chaparro

Esteve

2011

Alimentary Pharmacology &Amp; Therapeutics

105

View full text Add to dashboard Cite

“…Biancone et al [7] found that IBD population had higher prevalence of hepatitis B surface antibody (HBsAb) than controls [7] , and studies conducted in endemic areas have reported a rate of present and past HBV infection of 40% [8] . Conversely, recent researches in Spain and France describe exposure rates similar to the general population [9,10] , while Kim et al [11] , in South Korea, cannot find IBD as a risk factor for HBV, with a reported prevalence of hepatitis B surface antigen (HBsAg) of 3.7% in IBD vs 4.4% in the control group [11] . In rheumatic diseases, the HBV status has also been evaluated.…”

Section: Diseasesmentioning

confidence: 97%

Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy

López-Serrano

Briongos

Alonso

et al. 2015

WJH

View full text Add to dashboard Cite

Currently immunosuppressive and biological agents are used in a more extensive and earlier way in patients with inflammatory bowel disease, rheumatic or dermatologic diseases. Although these drugs have shown a significant clinical benefit, the safety of these treatments is a challenge. Hepatitis B virus (HBV) reactivations have been reported widely, even including liver failure and death, and it represents a deep concern in these patients. Current guidelines recommend to preemptive therapy in patients with immunosuppressants in general, but preventive measures focused in patients with corticosteroids and inflammatory diseases are scarce. Screening for HBV infection should be done at diagnosis. The patients who test positive for hepatitis B surface antigen, but do not meet criteria for antiviral treatment must receive prophylaxis before undergoing immunosuppression, including corticosteroids at higher doses than prednisone 20 mg/d during more than two weeks. Tenofovir and entecavir are preferred than lamivudine because of their better resistance profile in long-term immunosuppressant treatments. There is not a strong evidence, to make a general recommendation on the necessity of prophylaxis therapy in patients with inflammatory diseases that are taking low doses of corticosteroids in short term basis or low systemic bioavailability corticosteroids such as budesonide or beclomethasone dipropionate. In these cases regularly HBV DNA monitoring is recommended, starting early antiviral therapy if DNA levels begin to rise. In patients with occult or resolved hepatitis the risk of reactivation is much lower, and excepting for Rituximab treatment, the prophylaxis is not necessary. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapyCore tip: Few reviews have been published including data of the three more common inflammatory diseases that require immunosuppressive therapy: inflammatory bowel disease, rheumatic and dermatologic diseases. This paper is focused on the risk of reactivation of hepatitis B virus under immunosuppressants, and particularly corticosteroids. Although most of the guidelines do not specify the necessity of prophylaxis in case of monotherapy with corticosteroids, the specialists responsible of these patients are usually concerned about this issue. Moreover, the risk with low systemic bioavailability new corticosteroids has not been evaluated in previous reviews. This work summarizes the evidence of VHB reactivation in patients with inflammatory diseases: when and how to apply prophylaxis, with a special focus on "new" and "old" steroids.López-Serrano P, de la Fuente Briongos E, Carrera-Alonso E, Pérez-Calle JL, Fernández Rodríguez C. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

show abstract

Hepatitis B reactivation in patients with inflammatory bowel disease

Poupardin¹,

Nahon

Pariente

et al. 2011

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France

Cited by 82 publications

References 45 publications

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease

Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy

Hepatitis B reactivation in patients with inflammatory bowel disease

Contact Info

Product

Resources

About